Pramipexole Dihydrochloride Hydrate/Rasagiline Mesylate

盐酸普拉克索/甲磺酸雷沙吉兰

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePramipexole Dihydrochloride Hydrate/Rasagiline Mesylate
Drug Alias NameRasagaline/pramipexole盐酸普拉克索/甲磺酸雷沙吉兰Rasagiline Mesylate/Pramipexole Dihydrochloride HydratePramipexole/RasagilineP2B-001
ClassificationSmall molecules
Mechanisms of ActionDopamine D3 receptor agonistsDopamine D4 receptor agonistsDopamine D2 receptor agonists +[4] 
TargetsMonoamine oxidase BDopamine D2 receptorDopamine D4 receptor +[4] 
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany +[6] 
CombinationsYes Rasagiline MesylatePramipexole Dihydrochloride Hydrate
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPharma Two B Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMyung In Pharmaceutical CompanyPharma Two B LtdZhejiang Jingxin Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A